Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data

BACKGROUND: Ocrelizumab (OCR) is the only disease-modifying therapy (DMT) for both relapsing and primary progressive forms of multiple sclerosis (MS). OCR is given by intravenous (IV) infusion twice a year, which may improve adherence to the dosing schedule relative to other MS DMTs that require mor...

Descripción completa

Detalles Bibliográficos
Autores principales: Engmann, Natalie J, Sheinson, Danny, Bawa, Komal, Ng, Carmen D, Pardo, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394226/
https://www.ncbi.nlm.nih.gov/pubmed/33624535
http://dx.doi.org/10.18553/jmcp.2021.20413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394226/
https://www.ncbi.nlm.nih.gov/pubmed/33624535
http://dx.doi.org/10.18553/jmcp.2021.20413

Ejemplares similares